Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Medarex
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Detectable HIV viremia (HIV-1 RNA level between 1,000 and 100,000 copies/mL)
CD4 count greater than or equal to 100 cells/mm3
Current antiretroviral therapy regimen following at least 2 previous changes for documented virologic failure
Documented resistance tests demonstrating the presence of at least 1 mutation to each major therapeutic class of antiretroviral therapy
No significant organ compromise
You may not be if
Initiation of any new medications that might reasonably affect the immune response or viral load within 4 weeks prior to screening
Tetanus booster immunization within 2 months of screening, or a history of anaphylaxis or severe local reaction to the tetanus vaccine
History of autoimmune disease at risk for recurrence
Current malignancy, except Stage A or B cervical carcinoma or basal cell carcinoma
Chronic viral hepatitis, due to Hepatitis B or Hepatitis C undergoing current treatment or Hepatitis B DNA greater than 25 pg/cc or Hepatitis C RNA greater than 20,000 IU/cc
Currently undergoing treatment or prophylaxis for tuberculosis infection
Chronic active infectious disease (other than HIV)
Clareo Health | A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
